Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06317896
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-19
First Post:
2024-03-12
Brief Title:
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
Sponsor:
Zhujiang Hospital
Organization:
Zhujiang Hospital
Study Overview
Official Title:
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS a Prospective Cohort Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
On the basis of previous retrospective studies the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin CTC-DNA of recurrentmetastatic foci derived from CTCs at the molecular level in hepatocellular carcinoma prospective clinical trials will be conducted to further validate the predictive value of the CTCS longitudinal monitoring model in predicting postoperative recurrence of hepatocellular carcinoma and to verify whether it is earlier than imaging to indicate recurrence to explore the clinical feasibility of CTCs in guiding postoperative adjuvant therapy of liver cancer and to provide new ideas for early intervention strategy of liver cancer after operation to establish a set of standardized clinical scheme of auxiliary treatment for patients with liver cancer after operation for accurate and individualizedEarly diagnosis and treatment
Detailed Description:
The recurrence rate of HCC after radical resection is high MRD is the root cause of HCC recurrence and the MRD result is an important basis for auxiliary treatment decision-making after radical resection On the basis of previous retrospective studies the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin CTC-DNA of recurrentmetastatic foci derived from CTCs at the molecular level in hepatocellular carcinoma prospective clinical trials will be conducted to further validate the predictive value of the CTCS longitudinal monitoring model in predicting postoperative recurrence of hepatocellular carcinoma and to verify whether it is earlier than imaging to indicate recurrence to explore the clinical feasibility of CTCs in guiding postoperative adjuvant therapy of liver cancer and to provide new ideas for early intervention strategy of liver cancer after operation to establish a set of standardized clinical scheme of auxiliary treatment for patients with liver cancer after operation for accurate and individualizedEarly diagnosis and treatment to provide high-quality evidence-based medicine for the clinical practice of preventing recurrence after radical hepatectomy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None